TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01592448

Intervention type: BEHAVIORAL
Intervention: Active Ingredient Icon
Description: Enhanced bottles will have a symbol, or icon, designed to draw attention to active ingredient information. The icon is a black hexagon containing two letters denoting the active ingredient of the medication (i.e. Ac for acetaminophen). Over-the-counter bottles will have the icon placed on the front of the bottle next to active ingredient information and on the back of the bottle in the drug facts to the left of the active ingredient information. Prescription bottles will have the icon placed below the directions for how to take the medication and will be accompanied by a brief statement indicating the medicine contains acetaminophen.

Intervention type: BEHAVIORAL
Intervention: Active Ingredient Icon
Description: Enhanced bottles will have a symbol, or icon, designed to draw attention to active ingredient information. The icon is a black hexagon containing two letters denoting the active ingredient of the medication (i.e. Ac for acetaminophen). Over-the-counter bottles will have the icon placed on the front of the bottle next to active ingredient information and on the back of the bottle in the drug facts to the left of the active ingredient information. Prescription bottles will have the icon placed below the directions for how to take the medication and will be accompanied by a brief statement indicating the medicine contains acetaminophen.
Study: NCT00736944

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation (Post induction)
Description: Monday-Friday, weeks 1-7

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation (Post induction)
Description: Monday-Friday, weeks 1-7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: (Post induction) Cisplatin 100 mg/m2 IVPB on radiation day 1, 22 and 42

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: (Post-induction) Cetuximab (for patients who cannot receive cisplatin) will begin (+/- 3 days) before starting radiation therapy at 400 mg/m2 IVPB. Subsequent doses of cetuximab will be given weekly at 250 mg/m2 IVPB
Study: NCT03892187

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Walking prescriptions plus weekly coaching calls prior to surgery.
Study: NCT02340221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500 mg was administered as two IM injections of 250 mg each as per the schedule specified in the respective arms.
Study: NCT02549573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APOKYN
Description: Subjects in the APOKYN+ group will administer his/her usual dose of APOKYN at the PT clinic, as instructed by the Physical Therapist. These subjects will not take carbidopa/levodopa for at least 3 hours before or during the PT Intervention Visit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: All subjects will participate in a standardized PT intervention
Study: NCT03750955

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plaque induced gingivitis
Description: Non-invasive microimaging (OTC device) of gingival tissue where oral hygiene cessation utilizing localized stent-induced biofilm overgrowth model (SIBO), will manipulate the participants' oral environment by leading to reversible inflammation of the gingival tissues.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oral hygiene maintenance
Description: Non-invasive microimaging (OTC device) of gingival tissue where oral hygiene has been maintained by tooth brushing with fluoride toothpaste and flossing twice daily.
Study: NCT02549573

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical Therapy
Description: All subjects will participate in a standardized PT intervention
Study: NCT03297671

Intervention type: DRUG
Intervention: RhIg prophylaxis
Description: Two RhIg prophylaxis injections for Rh negative women

Intervention type: DRUG
Intervention: RhIg prophylaxis
Description: Two RhIg prophylaxis injections for Rh negative women

Intervention type: DEVICE
Intervention: ELDONCARD
Description: ELDONCARD point-of-care test.

Intervention type: DEVICE
Intervention: ELDONCARD
Description: ELDONCARD point-of-care test.

Intervention type: DIAGNOSTIC_TEST
Intervention: ELDONCARD Test
Description: LHVs will perform ELDONCARD test.

Intervention type: DIAGNOSTIC_TEST
Intervention: ELDONCARD Test
Description: LHVs will perform ELDONCARD test.
Study: NCT04251091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill walking
Description: Up to 5 bouts of 6 minutes walking on the treadmill with rest breaks allowed between sets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overground Walking
Description: Up to 5 bouts of 6 minutes walking overground with rest breaks allowed between sets
Study: NCT02970435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Discharge Instructions
Description: The video discharge instructions, will be provided to the patient at the time of surgical procedure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telecommunication Reminders
Description: Telecommunication reminders including text messages, email, or phone calls to remind participants how to access the video discharge instruction up to three times before follow-up

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care: verbal and written discharge instructions for patients after surgery

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care: verbal and written discharge instructions for patients after surgery
Study: NCT03736187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: Giving cephalexin and metronidazole in one group \&cephalexin alone in another group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: Giving cephalexin and metronidazole in one group \&cephalexin alone in another group
Study: NCT01330667

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutramigen Infant Formula
Description: Investigators will advise to supplement with 10cc's of extensively hydrolyzed formula immediately following each breastfeeding until TSB declines.
Study: NCT04210505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine Topical Ointment
Description: Intranasal povidone-iodine will be applied to the lower anterior nares (i.e. nostril) of patients undergoing hemodialysis before each session.
Study: NCT02443935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGN1703
Description: 60 mg s.c. twice weekly for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGN1703
Description: 60 mg s.c. twice weekly for 24 weeks
Study: NCT04005300

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: standard enteral nutrition
Description: Enteral nutrition was treated within 48 hours after ICU and the calories were 500-750kcal/d

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: restricted enteral nutrition
Description: Enteral nutrition was treated within 48 hours after ICU and the calories were 10-20kcal/kg/d for 3 days
Study: NCT03701243

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mNT-BBAVF
Description: Briefly, to construct an mNT-BBAVF, an incision is made on the ulnar side of the elbow. The brachial artery and basilic vein are then isolated, and a side-to-side anastomosis is performed without transposition of the basilic vein.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RCAVF
Description: Briefly, to construct a wrist RCAVF, an incision is made on the radial side of the wrist. The radial artery and cephalic vein are then isolated, and a end-to-side anastomosis is performed.
Study: NCT03961308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vedolizumab SC
Description: Vedolizumab SC liquid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab SC
Description: Vedolizumab SC liquid.
Study: NCT03537443

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol (vitamin D3)
Description: Prenatal and postpartum supplementation with vitamin D3 and/or placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D3)
Description: Prenatal and postpartum supplementation with vitamin D3 and/or placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D3)
Description: Prenatal and postpartum supplementation with vitamin D3 and/or placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D3)
Description: Prenatal and postpartum supplementation with vitamin D3 and/or placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D3)
Description: Prenatal and postpartum supplementation with vitamin D3 and/or placebo.
Study: NCT00822380

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron
Description: Daily 20mg of ferrous sulfate in liquid solution during 4 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients supplement
Description: Daily supplement with 10mg of iron plus several micronutrients following a formula designed to treat anemia in indigenous population in Mexico. During 4 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: micronutrient fortified porridge powder
Description: Daily powdered complementary food designed for a national program in Mexico with 10mg of iron plus several micronutrients during 4 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron and ascorbic acid fortified water
Description: A drink water product fortified with 6.7 mg ofiron, zinc and ascorbic acid. This product was asked to be used for drinking and for cooking for the child during 4 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron plus folic acid supplement
Description: Daily liquid solution following the daily iron (12.5mg)and folic acid recommendation of UNICEF to treat anemia during 4 months
Study: NCT02351089

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Capsules placebo
Description: Capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Capsules probiotic powder and corn starch

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Capsules probiotic powder and corn starch
Study: NCT04509258

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl cysteine
Description: a drug which can have an off label use as an antidot for aluminium phosphide poisoning in addition to sodium bicarbonate and ondansetron as standard of care

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: acetyl L-carnitine
Description: Naturallu occuring amino acid derivative which can be taken as a dietary supplement involves in mitochondrial function and energy production and is suggested to have a role in lowering organ damage resulting from aluminium phosphide poisonong in addition to sodium bicarbonate and ondansetron as standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medicated paraffin oil
Description: refined mixture of liquid hydrocarbons which used as laxative and is suggested to reduce absorption of aluminium phosphide if taken within two hours of administration of the toxin in addition to sodium bicarbonate and ondansetron as standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate Powder and ondansetron
Description: standard of care for treatment of aluminuim phosphide is provided for patients poisoned with aluminuim phosphide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate Powder and ondansetron
Description: standard of care for treatment of aluminuim phosphide is provided for patients poisoned with aluminuim phosphide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate Powder and ondansetron
Description: standard of care for treatment of aluminuim phosphide is provided for patients poisoned with aluminuim phosphide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Bicarbonate Powder and ondansetron
Description: standard of care for treatment of aluminuim phosphide is provided for patients poisoned with aluminuim phosphide
Study: NCT04210505

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Control group will receive standard care as provided by the dialysis center
Study: NCT04236973

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Molbio Truenat™ HCV assay (the investigational product)
Description: The Molbio Truenat™ HCV assay (the investigational product) is a quantitative chip-based Real Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR) tests for the detection of HCV genomic RNA from human whole blood, EDTA plasma and serum. The Truenat™ HCV assay runs on the Truelab™ Uno, Truelab™ Duo or Truelab™ Quadro Dx. Results of testing by Truenat™ HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Abbott RealTime HCV assay
Description: Plasma specimens will be also tested on Abbott RealTime HCV assay that is approved for HCV diagnostics use by countries' authorities. Only the results of Abbott RealTime HCV assay may be used to make clinical decisions.
Study: NCT00003432

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: carcinoembryonic antigen RNA-pulsed DC cancer vaccine
Description: Approximately 60-90 days after the peripheral blood stem cell transplant, patients receive CEA RNA pulsed dendritic cells IV every 3 weeks for a total of 4 doses.
Study: NCT03389191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Study: NCT03411291

Intervention type: DEVICE
Intervention: MRI, MR Spectroscopy, MR Perfusion
Description: One brain MRI/MR Spectroscopy/MR Perfusion at baseline and one brain MR/MR Spectroscopy/MR Perfusion at 3 months.
Study: NCT04217850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 250 kcal Dietary Energy Restriction
Description: The nutrition intervention will be individualized and implemented as a free-living energy-restricted eating plan where energy intake will be based on a mild restriction (approx. 250 kcal/day).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Supervised aerobic exercise will be combined with the energy restriction. Individuals will perform aerobic exercise (treadmill, cycle, or rower or combination) 4-5 days per week for 12 weeks. At each session they will expend 250 or more calories to further meet or exceed the 500 kcal energy deficit.
Study: NCT00718939

Intervention type: DEVICE
Group type: OTHER
Intervention: Rheos Baroreflex Activation Therapy System
Description: The two (2) Rheos Carotid Sinus Leads conduct the activation energy from the Rheos Implantable Pulse Generator to the baroreceptors located on the left (Left Carotid Sinus Lead) and right (Right Carotid Sinus Lead) carotid sinus. This energy activates the baroreflex by inducing signals that the brain interprets as elevated blood pressure.

Intervention type: DEVICE
Group type: OTHER
Intervention: Rheos Baroreflex Activation Therapy System
Description: The two (2) Rheos Carotid Sinus Leads conduct the activation energy from the Rheos Implantable Pulse Generator to the baroreceptors located on the left (Left Carotid Sinus Lead) and right (Right Carotid Sinus Lead) carotid sinus. This energy activates the baroreflex by inducing signals that the brain interprets as elevated blood pressure.
Study: NCT04329130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide, Lenalidomide
Description: All patients enrolled in the study will accept Chidamide combination with lenalidomide regimen.
Study: NCT02444598

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaccum Assisted Closure device
Description: Negative-pressure wound therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional wound dressings
Description: Conventional wound dressings
Study: NCT00857545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polyvalent Antigen-KLH Conjugate Vaccine
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saponin-based Immunoadjuvant OBI-821
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saponin-based Immunoadjuvant OBI-821
Description: Given SC
Study: NCT03207672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389-LF
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389-LF
Description: intravenous infusion
Study: NCT03929770

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: with pause
Description: When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner pause the advancement for 10 sec. Next, the practitioner re-advance it to the pulmonary artery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: without pause
Description: When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner advance it continuously without pause to the pulmonary artery.
Study: NCT03071653

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left Cardiac Sympathetic Denervation (LCSD)
Description: The procedure involves the surgical removal of the lower half of the left stellate ganglion (T1) and thoracic ganglia (T2-T4), thereby removing the pro-arrhythmic noradrenergic input to the ventricles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Therapy
Description: All eligible patients with heart failure and depressed left ventricular systolic function will receive guideline and evidence based optimal tolerated medical therapy. The level of risk associated with optimal medical therapy is considered very low. For the majority of patients with heart failure and depressed left ventricular systolic function this will include:~1. A renin angiotensin system blocker at highest tolerated doses (e.g., enalapril 10mg twice daily or equivalent)~2. A mineralocorticoid receptor antagonist (e.g., Spironolactone 25-50mg daily or equivalent)~3. A Beta-blocker (e.g., Carvedilol 25mg twice daily or equivalent)~4. The use of a loop diuretic and digitalis will be clinically driven and used at the discretion of the attending clinician

Intervention type: OTHER
Group type: OTHER
Intervention: Optimal Medical Therapy
Description: All eligible patients with heart failure and depressed left ventricular systolic function will receive guideline and evidence based optimal tolerated medical therapy. The level of risk associated with optimal medical therapy is considered very low. For the majority of patients with heart failure and depressed left ventricular systolic function this will include:~1. A renin angiotensin system blocker at highest tolerated doses (e.g., enalapril 10mg twice daily or equivalent)~2. A mineralocorticoid receptor antagonist (e.g., Spironolactone 25-50mg daily or equivalent)~3. A Beta-blocker (e.g., Carvedilol 25mg twice daily or equivalent)~4. The use of a loop diuretic and digitalis will be clinically driven and used at the discretion of the attending clinician
Study: NCT01512810

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Description: Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
Study: NCT03216538

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AS101 1% oral solution
Description: 0.4 ml daily p.o.
Study: NCT03425955

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SUNEKOS ® 200
Description: 4 micro-injection sessions of SUNEKOS® 200 with an interval of 10 days. Two different injection techniques were carried out mono-laterally on the left or right face side randomly: interstitial fluid technique (IFT) on one face side; bolus technique on five pre-determined face points (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) on the contralateral face side.
Study: NCT03900806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online cognitive rehabilitation
Description: The cognitive rehabilitation program will be based on the protocol of a frequently used meta-cognitive strategy approach applied in many rehabilitation centers in the Netherlands. The program consists of several modules that can be used in a flexible way, depending on the specific individual problems and goals. Therapists have undergone additional training in issues related to cancer-related cognitive impairment and problems occupationally active cancer survivors might experience at work. In both intervention arms, participants will receive access to a secured personal webpage, where all content relevant to the treatment sessions can be obtained.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online cognitive rehabilitation
Description: The cognitive rehabilitation program will be based on the protocol of a frequently used meta-cognitive strategy approach applied in many rehabilitation centers in the Netherlands. The program consists of several modules that can be used in a flexible way, depending on the specific individual problems and goals. Therapists have undergone additional training in issues related to cancer-related cognitive impairment and problems occupationally active cancer survivors might experience at work. In both intervention arms, participants will receive access to a secured personal webpage, where all content relevant to the treatment sessions can be obtained.
Study: NCT03425955

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SUNEKOS® 1200 and SUNEKOS® 200
Description: 5 micro-injection sessions (one of the product SUNEKOS® 1200 and four of SUNEKOS® 200. SUNEKOS® 1200 was injected bi-laterally on the face with cushion technique. 24 hours after the SUNEKOS® 1200 treatment, 4 micro-injection sessions of SUNEKOS® 200 with an interval of 10 days were performed . SUNEKOS® 200 was injected with two different techniques, carried out mono-laterally on the left or right face side randomly: retrograde interstitial fluid technique (RIFT) on one face side; bolus technique on five pre-determined face points (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) on the contralateral face side.
Study: NCT01728103

Intervention type: DEVICE
Intervention: APTIMA® Trichomonas vaginalis & APTIMA® COMBO 2® Assays
Description: In Vitro Diagnostic Assays